KD-347

KD-347 is a fourth-generation chimeric antigen receptor T-cell (CAR-T) therapy currently in preclinical development by KAEDI Medical. As a fourth-generation CAR-T (often referred to as TRUCKs—T-cells redirected for universal cytokine killing), it is designed to not only target specific tumor antigens but also to incorporate additional genetic modifications, such as the inducible expression of cytokines, to enhance anti-tumor activity and overcome the immunosuppressive tumor microenvironment. While the specific molecular target for KD-347 remains undisclosed by the developer, the platform aims to address challenges in treating solid tumors or refractory hematological malignancies.